Drug Profile


Alternative Names: CS-3150; XL-550

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Daiichi Sankyo Company; Exelixis
  • Class Antihyperglycaemics; Antihypertensives; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic nephropathies; Essential hypertension; Hyperaldosteronism; Hypertension
  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 24 Sep 2017 Phase-III clinical trials in Diabetic nephropathies (Treatment-experienced) in Japan (PO) (JapicCTI-173695)
  • 24 Sep 2017 Daiichi Sankyo announces intention to submit regulatory application to Japanese regulatory authority for Essential hypertension in the first quarter of 2018
  • 22 Sep 2017 Daiichi Sankyo initiates enrolment in a phase III safety trial for Hypertension (in type 2 diabetic patients with macroalbuminuria) in Japan (PO) (JapicCTI-173696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top